Jesy Nelson Celebrates Major NHS Milestone for Newborn SMA Screening
Singer Jesy Nelson has hailed a significant breakthrough in her campaign for the NHS to implement heel prick testing on newborn babies for spinal muscular atrophy (SMA), a rare and severe muscle-wasting condition. The 34-year-old artist, who revealed in January that her nine-month-old twins, Ocean and Story, were diagnosed with SMA Type 1, has been a vocal advocate for expanding screening to enable earlier diagnosis and treatment.
Devastating Diagnosis and Campaign Efforts
Jesy's twins received a late diagnosis, which means they are likely never to walk and require specialist equipment to assist with breathing at night, along with feeding tubes. This prognosis has driven her tireless efforts to push for change within the healthcare system. Despite the UK's National Screening Committee rejecting calls to introduce checks for another muscular disease in January, Health Secretary Wes Streeting announced on Wednesday that plans are in place to screen more than 400,000 babies for SMA from October 2026.
This decision follows persistent calls from campaigners, including Jesy, urging the health secretary to overrule the committee's guidance and make effective treatments more accessible through the NHS. In a letter addressed to Jesy and Giles Lomax, chief executive of SMA UK, Streeting confirmed that the in-service evaluation of SMA screening will now commence in October this year, rather than January 2025 as initially planned.
Celebrating the Victory on Social Media
Celebrating the news, Jesy took to her Instagram to express her joy, writing: 'A big step forward for SMA, ISE have announced to start screening for SMA in England will now begin in October 2026. I am so proud as this is a major milestone for the SMA community.' Her campaign has focused on expanding the NHS's current heel prick tests, which are conducted on babies at around five days old to check for just 10 treatable conditions, including cystic fibrosis.
The pilot programme will see an estimated 400,000 babies tested in England, marking a substantial expansion in neonatal screening. Jesy has described caring for her twins as an emotional rollercoaster, with some days being particularly challenging, but she remains hopeful that her daughters will defy the odds now that they are receiving treatment.
Understanding Spinal Muscular Atrophy
Spinal Muscular Atrophy is a disease that weakens a patient's strength by affecting the motor neuron cells in the spinal cord, leading to gradual muscle wasting. The severity of symptoms varies by type:
- Type 1 SMA: The most severe form, evident at birth, often preventing sitting and typically leading to death by age five.
- Type 2 SMA: An intermediate form where sufferers cannot stand.
- Type 3 SMA: A mild form that makes it difficult to rise from a sitting position.
- Type 4 SMA: Symptoms do not appear until patients are in their 20s or 30s.
Jesy's twins have Type 1, which underscores the urgency of early detection. In a recent Q&A, she explained that despite the devastating prognosis—her daughters may not live beyond age two—she has chosen to continue filming her Prime Video series to raise awareness and 'make a change.' She stated, 'When the girls got their diagnosis, we decided that we wanted to continue filming. As hard as it was, we were like, "You know what? There's a reason you guys are here, and we've got to make the best out of this situation."'
Daily Struggles and Hopeful Outlook
Jesy has openly shared the daily struggles of caring for her twins, noting that medical procedures often leave her feeling as though she is hurting them as they cry and scream. She described the experience as intense and full-on, a sentiment echoed in her discussions on podcasts like Jamie Laing's Great Company, where she expressed hope that her babies will defy expectations and achieve a longer life expectancy through treatment.
This announcement represents a pivotal moment in public health, driven by advocacy and personal tragedy. It highlights the importance of expanding screening programmes to improve outcomes for rare conditions, ensuring that future families can benefit from earlier interventions and support.
